Business
Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2025 on Thursday, August 28, 2025, at 08:00 a.m. CET.
About this update from Bioarctic Ab Class B
[{"type":"text","content":"STOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2025 on Thursday, August 28, 2025, at 08:00 a.m. CET.","length":211,"tagName":"p"},{"type":"text","content":"In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on August 28, at 09:30 CET, where Gunilla Osswald, CEO, Anders Martin-Löf, CFO, and colleagues will present and comment on the second quarter report, followed by a Q&A-session.","length":308,"tagName":"p"},{"type":"text","content":"If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.Webcast: https://bioarctic.events.inderes.com/q2-report-2025/register","length":195,"tagName":"p"},{"type":"text","content":"If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.https://events.inderes.com/bioarctic/q2-report-2025/dial-in","length":301,"tagName":"p"},{"type":"text","content":"The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.com/en/investors/financial-reports-and-presentations/ after the presentation.","length":181,"tagName":"p"},{"type":"text","content":"For more information, please contact:Oskar Bosson, VP Communications and Investor RelationsE-mail: [email protected] Tel: + 46 704 10 71 80","length":162,"tagName":"p"},{"type":"text","content":"This information was submitted for publication at 09:00 a.m. CET on August 21, 2025.","length":84,"tagName":"p"},{"type":"text","content":"About BioArctic AB","length":18,"tagName":"p"},{"type":"text","content":"BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interacti...